FDA Regulatory Status and Safety Update for Peptides

Clinical Question

What is the current regulatory status of commonly used peptides, and what safety signals have been identified in recent post-marketing surveillance and clinical trials?

Evidence Snapshot

• FDA Approved Compounds: Semaglutide (Ozempic, Wegovy, Rybelsus).
• Compounding Restrictions (503A/503B): Multiple compounds, including GHRP-2, GHRP-6, BPC-157, and Melanotan II, are currently listed in Category 2, indicating significant safety risks or lack of data.
• Safety Signals: Emerging signals for semaglutide include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and pulmonary aspiration.
• Clinical Outcomes: Phase III data for semaglutide shows 14.9% weight loss (STEP 1) and 20% MACE reduction (SELECT).

What the Research Shows

Regulatory Status and Compounding Restrictions

As of September 2026, the FDA has clarified the regulatory landscape for several compounds. Semaglutide is FDA-approved for chronic weight management, type 2 diabetes, and cardiovascular risk reduction. However, the FDA has noted that semaglutide sodium and semaglutide acetate are different active ingredients from the approved versions and lack a lawful basis for compounding. The national shortage-related compounding period for semaglutide has ended.

Several peptides are classified under Category 2 bulk drug substances, which the FDA identifies as presenting significant safety risks. These include:

• GHRP-2 and GHRP-6: Cited for immunogenicity concerns (September 2023).
• BPC-157: Reviewed by the Pharmacy Compounding Advisory Committee (PCAC) in July 2026. Concerns include immunogenicity, peptide-related impurities, and limited human safety information.
• Melanotan II: Cited for multiple serious adverse events; safety warnings have been issued by both the FDA and TGA.
• KPV: Nomination was withdrawn and the substance was removed from Category 2, followed by a PCAC review in July 2026.
• LL-37 and MK-677: Both are in Category 2 due to safety concerns.

Safety Signals and Adverse Events

For semaglutide, the FDA Adverse Event Reporting System (FAERS) and post-marketing surveillance have identified several signals. Strong signals exist for nausea, vomiting, and delayed gastric emptying. More serious signals include acute pancreatitis and intestinal obstruction (ileus), the latter of which was added to the label post-marketing.

Emerging safety signals for semaglutide include:

• NAION: 96 cases reported through December 2024; under EMA review as of January 2025.
• Pulmonary Aspiration: Added to the Ozempic label in 2025 due to risks during general anesthesia related to delayed gastric emptying.
• Acute Kidney Injury: Often detected in the context of GI-related dehydration.

Clinical Trial Summary

Clinical trials have established efficacy benchmarks for several agents. Semaglutide achieved 14.9% weight loss in the STEP 1 trial and a 20% reduction in Major Adverse Cardiovascular Events (MACE) in the SELECT trial. Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial and was found superior to semaglutide in the SURMOUNT-5 trial. Retatrutide showed 24.2% weight loss at a 12mg dose in Phase II, with Phase III trials (TRIUMPH-3) currently active.

In contrast, Thymosin Alpha 1 failed to show mortality reduction in the Phase III TESTS trial for sepsis. Tesamorelin demonstrated an 18% reduction in visceral adipose tissue (VAT) in pivotal Phase III trials for HIV lipodystrophy.

Mechanism

The provided data does not contain specific molecular mechanisms for these compounds beyond their clinical indications and regulatory safety concerns.

Limitations of the Evidence

Evidence for research peptides like BPC-157 and KPV is limited by a lack of robust human safety data and uncertainties regarding peptide-related impurities. Many safety signals for semaglutide, such as NAION and suicidal ideation, are currently under evaluation or formal review and have not yet been definitively linked to a higher risk compared to background rates in all populations.

Clinical Takeaway

Physicians should note that many peptides previously used in compounding, such as GHRP-2, GHRP-6, and BPC-157, are now classified as Category 2 substances due to immunogenicity and safety concerns. For approved agents like semaglutide, clinical focus should remain on monitoring for emerging signals such as intestinal obstruction and perioperative aspiration risk.

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Sources

1. FDA: Certain bulk drug substances that may present significant safety risks.
2. FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee.
3. PMID: 33567185 (STEP 1 Trial).
4. PMID: 37952131 (SELECT Trial).
5. PMID: 35658024 (SURMOUNT-1 Trial).
6. FDA: Medications containing semaglutide marketed for type 2 diabetes or weight loss.

Physicians seeking to understand local availability should investigate how to find a peptide prescriber who adheres to current FDA 503A and 503B guidelines. For more information on sourcing, visit peptide therapy near me.